SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is experiencing heightened attention amid intense public debate surrounding a controversial incident involving federal agents in Minneapolis, with community discussion highlighting conflicting accounts and broader concerns about government authority. This narrative is further amplified by ongoing political discourse around its namesake's actions and international trade policies, creating a highly charged environment. Investors and observers are closely monitoring these developments for their potential implications on the political landscape.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics (CVKD) is trending amid discussions surrounding recent advancements in its cardiovascular drug pipeline, notably progress with tecarfarin manufacturing and the acquisition of VLX-1005 for heparin-induced thrombocytopenia. The community is sharply divided, with some investors bullish on its novel anticoagulants, FDA Fast Track designation, and strategic collaborations, while a skeptical contingent points to historical performance and concerns over recurring funding needs. Traders are closely watching its ultra-low float for potential volatility, balancing a perceived significant market opportunity against ongoing financial uncertainties.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is currently trending due to intense speculation surrounding an improved acquisition offer from Sanofi, following reports of a rejected $16/share bid. The community is highly optimistic about upcoming Phase 3 data for AXPAXLI in wet AMD, especially given the company's accelerated NDA strategy and the recent high-profile hire of a former Eylea architect. Investors are actively discussing the potential of AXPAXLI to redefine long-acting retinal therapy, fueling expectations for a substantial premium or strong independent commercialization, making it a focal point of market interest.

TKO Group Holdings, Inc. engages in the provision of sports and entertainment. It operates through the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE) segments. The UFC segment refers to a global sports brand and media content company. The WWE segment is involved in media organization and global leader in sports entertainment. The company was founded on March 29, 2023 and is headquartered in New York, NY.

TKO Group Holdings Inc - Ordinary Shares - Class A

TKO GROUP HLDGS INC

TKO Group Holdings is trending following its recent inclusion in the S&P 500 and a significant, fan-friendly Paramount+ deal that makes UFC events more accessible without pay-per-view. The community is buzzing about these strategic moves as major catalysts, fueling optimism for the company's growth in the competitive sports and entertainment sector. Strong insider buying further reinforces confidence in TKO's expanding global footprint and revenue potential.

Eversource Energy engages in the generation, transmission, and distribution of natural gas and electricity. It operates through the following segments: Electric Distribution, Electric Transmission, Natural Gas Distribution, Water Distribution, and Other. The Electric Distribution segment distributes electricity to retail customers. The Electric Transmission segment owns and maintains transmission facilities through CL&P, NSTAR Electric, PSNH, and WMECO. The Natural Gas Distribution segment transmits and distributes natural gas to retail customers. The Water Distribution segment operates five separate regulated water utilities in Connecticut, Massachusetts, and New Hampshire. The company was founded on July 1, 1966, and is headquartered in Springfield, MA.

Eversource Energy

Eversource Energy is trending amid intense community discussions about its storm preparedness and service reliability, fueled by recent rate hikes and past power outages, while also facing scrutiny after Connecticut regulators rejected the sale of its Aquarion Water Company subsidiary. This regulatory setback has prompted concerns about the utility's capital funding, but the company's consistent dividend increases and strategic long-term investments in clean energy continue to attract interest from income-focused investors.

V2X, Inc. provides solutions and support to defense clients globally. It delivers integrated solutions across the operations and logistics, aerospace, training and technology markets to national security, defense, civilian and international clients. The company was founded in February 2014 and is headquartered in Reston, VA.

V2X Inc

V2X Inc. is trending amid a series of significant government contract wins, including a substantial Air Force T-6 aircraft program and key contributions to the Golden Dome and Greenland operations, bolstering its position in critical defense and mission support. Community discussions highlight the company's strong growth trajectory, strategic alignment with increasing defense spending, and perceptions of undervaluation following recent positive financial performance and favorable analyst sentiment.

PAW Chain has launched the world’s first Layer 3-centric blockchain, enhancing scalability and inter-chain operability across networks. The roadmap features a decentralized exchange, merchant services, and a DAO, all optimized for high-volume, low-cost transactions. Leveraging smart contracts and EVM compatibility, PAW Chain is set to transform digital finance by providing secure, efficient solutions, allowing any project to go multi-chain, underscored by a community-driven governance model and rigorous security standards including regular security audits.

PAW CRYPTO is trending as its community eagerly anticipates an upcoming rebrand and significant Layer 1/Layer 3 ecosystem upgrades aimed at enhancing interoperability and utility. Investors are discussing its potential as a foundational, quantum-safe blockchain designed to bridge Web2 and Web3 for enterprise solutions, backed by recent validator launches and CertiK audit achievements. This strong focus on real-world infrastructure rather than just hype is fueling optimism for long-term growth.

Monad is a high-performance Layer 1 blockchain that processes 10,000 transactions per second with near-zero fees. The platform delivers high performance without compromising on security or decentralization, creating the infrastructure needed for complex applications that require high-frequency activity.  One of Monad’s key innovations lies in how it handles transaction processing. Instead of processing transactions one at a time like traditional blockchains, Monad processes multiple transactions simultaneously through parallel execution.   The system separates the agreement process from the execution process, allowing validators to first agree on which transactions to include and in what order, then having more time to execute those transactions without slowing down consensus. This approach, combined with a custom-built database called MonadDB, dramatically increases throughput while maintaining accuracy.  Monad also offers complete EVM compatibility, where applications built for Ethereum work on Monad without any code modifications, and users can connect with familiar wallets like MetaMask just as they would on Ethereum. Developers can immediately tap into Ethereum's established ecosystem of tools, libraries, and applications while benefitting from Monad’s performance improvements. The platform also runs on consumer-grade hardware rather than expensive specialized equipment, making it accessible for more people to participate in securing the network.  Monad has raised approximately 244 million dollars in total funding across multiple rounds. The company secured 19 million dollars in a seed round in February 2023 led by Dragonfly Capital, followed by a 225 million dollar Series A round in April 2024 led by Paradigm at a 3 billion dollar valuation. Other notable investors include Electric Capital, Greenoaks, Coinbase Ventures, and prominent angel investors such as Naval Ravikant.

Monad

Monad is trending amidst discussions of recent large investor accumulation and a rapidly expanding ecosystem, marked by significant Total Value Locked and new dApp integrations like Kalshi and Orbs. The community is split, with many bullish investors seeing it as a long-term "ground floor" opportunity due to its EVM compatibility, high transaction speed, and strong venture capital backing, while others voice concerns over price volatility and future token dilution. As a Layer 1 blockchain, Monad aims to offer a scalable alternative, drawing attention from across the broader crypto market.

Velo3D, Inc. operates as a technology company, which engages in developing and manufacturing metal laser sintering printing machines for 3D printing. Its products include assure system, flow software, sapphire printer & sapphire XC. The company was founded by Benyamin Buller in June 2014 and is headquartered in Fremont, CA.

Velo3D Inc

Velo3D is drawing significant attention following a major $32.6 million Department of Defense contract aimed at resolving critical manufacturing bottlenecks and recent $30 million PIPE financing. The community is actively discussing the company's vital role in advanced metal additive manufacturing for aerospace and defense, including its established partnerships with SpaceX and emerging collaborations with defense innovators like Anduril. This positions Velo3D as an essential technology provider for resilient domestic supply chains and next-generation weapons systems.

Assemble’s AI agent, News3(NS3), was developed with the goal of revolutionizing Web 3.0 journalism. NS3 delivers crypto and global economic trends quickly and clearly, and leverages advanced AI reasoning capabilities to analyze these trends, enabling market participants to make data-driven decisions. In particular, NS3 utilizes OpenAI’s latest reasoning model as its core engine to analyze crypto and economic trends, providing a range of insights including market psychology, past case analysis, future predictions, ripple effects, and investment strategies in 12 languages.

Assemble Protocol

Assemble Protocol (ASM) is generating buzz amid intense community speculation around its AI developments, particularly concerning a "News3 AI agent" and rumored integrations with major tech platforms. Investors are closely monitoring "Asian whale" accumulation and potential Binance listing, balancing strong breakout hopes against a history of volatile price action.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Interesting ARQT Put And Call Options For September 18th

Investors in Arcutis Biotherapeutics Inc (Symbol: ARQT) saw new options become available this week, for the September 18th expiration. One of the key inputs that goes into the price an option buyer...

Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Unloaded Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (D-California) recently sold shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT). In a filing disclosed on January 12th, the Representative disclosed that...

Strength Seen in ANI (ANIP): Can Its 10.6% Jump Turn into More Strength?

ANI (ANIP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 7.3% - Here's What Happened

Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Down 7.3% - Here's Why...

Howard Welgus Sells 10,000 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) Stock

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) Director Howard Welgus sold 10,000 shares of the business's stock in a transaction that occurred on Friday, January 2nd. The stock was...

Arcutis Biotherapeutics (NASDAQ:ARQT) Raised to "Strong-Buy" at Wall Street Zen

Wall Street Zen upgraded Arcutis Biotherapeutics from a "buy" rating to a "strong-buy" rating in a report on Sunday...

Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Sells $49,552.40 in Stock

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) insider Patrick Burnett sold 1,697 shares of the company's stock in a transaction that occurred on Wednesday, December 31st. The shares...

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) has been given an average rating of "Moderate Buy" by the nine research firms that are presently covering the stock, MarketBeat Ratings...

Wednesday's ETF Movers: XBI, SLVR

In trading on Wednesday, the SPDR S&P Biotech ETF is outperforming other ETFs, up about 0.7% on the day. Components of that ETF showing particular strength include shares of Oruka Therapeutics, up...

Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Up 3.4% - Still a Buy?

Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Up 3.4% - Should You Buy...

Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its pipeline consists of topical treatments for plaque psoriasis, atopic dermatitis, hand eczema, vitiligo, scalp psoriasis, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne in June 2016 and is headquartered in Westlake Village, CA.

Arcutis Biotherapeutics Inc

$MSFT

$AAPL

$TSLA

$META

Earnings season is heating up, and several major companies report next week, including Microsoft, Apple, Tesla, and Meta. Which are you most excited for?

Which earnings report are you most excited for next week? 
 
Drop a comment for others.

ARQT
Arcutis Biotherapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ARQT News

ARQTArcutis Biotherapeutics Inc